InChIKey	JDUBGYFRJFOXQC-KRWDZBQOSA-N
Compound Name	Capivasertib
Canonical SMILES	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	13
Pfam Stratification	Cross-Family
Avg pChEMBL	6.84
Source	ChEMBL;BindingDB

DrugBank ID	DB12218
Drug Name	Capivasertib
CAS Number	1143532-39-1
Groups	approved investigational
ATC Codes	L01EX27
Description	Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, l...

---

Categories: Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates MATE 1 Inhibitors MATE 2 Inhibitors MATE inhibitors OAT3/SLC22A8 Inhibitors OATP1B1/SLCO1B1 Inhibitors OATP1B3 inhibitors OCT2 Inhibitors Protein Kinase Inhibitors Proto-Oncogene Proteins c-akt, antagonists & inhibitors UGT2B7 substrates

---

Cross-references: BindingDB: 50427349 CHEMBL2325741 ChemSpider: 28189073 Drugs Product Database (DPD): 23920 PDB: 0XZ PubChem:25227436 PubChem:347828497 RxCUI: 2669967 Wikipedia: Capivasertib ZINC: ZINC000043204023